Yingjie Zhang
Gender:Male
Education Level:Postgraduate (Doctoral)
Alma Mater:山东大学
Scientific Research
Paper Publications
-
. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer. Journal of Medicianal Chemistry, 66, 2024.
-
. Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity. J. Med. Chem. , 66, 10080, 2023.
-
Anil Kumar Marapaka. Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: Biological evaluation and structural characterization by cocrystallization. CHINESE CHEMICAL LETTERS, 2550, 2022.
-
薛霞. Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents. Investigational New Drugs , 40, 10-20, 2022.
-
许启富. Inhibitors of the GTPase KRAS(G12C) in cancer: a patent review (2019-2021). Expert Opinion on Therapeutic Patents, 32, 475, 2022.